<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02321839</url>
  </required_header>
  <id_info>
    <org_study_id>TAENCU001</org_study_id>
    <nct_id>NCT02321839</nct_id>
  </id_info>
  <brief_title>Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD.</brief_title>
  <official_title>Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nagoya City University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nagoya City University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the visual outcome, number of injections and visits, and the effect of mental
      status of a treat and extend regimen in managing neovascular age-related macular degeneration
      with intravitreal ranibizumab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treat and Extend Regimen (TER) may contribute to the improvement to a patients' mentality,
      since the treatment intervals are extended if there were no signs of recurrence. Therefore,
      we have planned to examine the psychological impact of TER using Hospital Anxiety and
      Depression Scale (HADS), in addition to the improvement of visual acuity and central retinal
      thickness.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>One Year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>central foveal thickness</measure>
    <time_frame>One and two years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Hospital Anxiety and Depression Scale</measure>
    <time_frame>one and two years</time_frame>
    <description>The mean change from baseline in Hospital Anxiety and Depression Scale at week 52 and 104.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Intraviteal Ranibizumab 0.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraviteal Ranibizumab 0.5mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intraviteal Ranibizumab 0.5mg</intervention_name>
    <description>Intraviteal Ranibizumab 0.5mg</description>
    <arm_group_label>Intraviteal Ranibizumab 0.5mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent form

          -  Male or female of aged 50 years or older

          -  Typical AMD and PCV patients

          -  BCVA of 24 letters or over

        Exclusion Criteria:

          -  Total lesion area of ＞12 DA or ＞30.5 mm2

          -  The existence of subretinal hemorrhage area constituting ≥50% of total lesion area

          -  The existence of scar or fibrosis area constituting ≥50% of total lesion area

          -  The existence of RPE tear

          -  Prior treatment for wet AMD

          -  History of vitrectomy surgery, submacular surgery, or other surgical intervention for
             AMD

          -  The pregnant or lactating woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuichiro Ogura</last_name>
    <role>Study Chair</role>
    <affiliation>Nagoya City Univsersity</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuichiro Ogura</last_name>
    <phone>+81-52-853-8251</phone>
    <phone_ext>8251</phone_ext>
    <email>ogura@med.nagoya-cu.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aki Kato</last_name>
    <phone>+81-52-853-8251</phone>
    <phone_ext>8251</phone_ext>
    <email>akikato@med.nagoya-cu.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sugita Eye Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>460-0008</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juntaro Sugita</last_name>
      <phone>+81-52-521-6571</phone>
    </contact>
    <contact_backup>
      <last_name>Iichiro Sugira</last_name>
      <phone>+81-52-521-6571</phone>
      <email>iichiro@sugita.or.jp</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Nagoya City Univsersity</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuichiro Ogura</last_name>
      <phone>+81-52-853-8251</phone>
      <phone_ext>8251</phone_ext>
      <email>ogura@med.nagoya-cu.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Aki Kato</last_name>
      <phone>+81-52-853-8251</phone>
      <phone_ext>8251</phone_ext>
      <email>akikato@med.nagoya-cu.ac.jp</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2014</study_first_submitted>
  <study_first_submitted_qc>December 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2014</study_first_posted>
  <last_update_submitted>October 19, 2016</last_update_submitted>
  <last_update_submitted_qc>October 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nagoya City University</investigator_affiliation>
    <investigator_full_name>Yuichiro Ogura</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>neovascular age-related macular degeneration</keyword>
  <keyword>Ranibizumab</keyword>
  <keyword>Treat and extend</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

